Najib Alidrissi

Followers

Following

251

Public Views

Pr Najib Al IDRISSI
Pr Najib Al IDRISSI obtained his doctorate in medicine at the Faculty of Medicine and Pharmacy of Rabat-Morocco in 2001.
Since 2006, he specialized in surgery orthopedic and traumatology and joined the Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco in 2016.
Pr Al Idrissi is director of Precision
Medicine and One Health Laboratory (MedPerOne), Faculty of Medicine, Mohammed VI University of Sciences and Health, Casablanca, Morocco
His research interests focus on digital health, precision medicine and One Health, cancer, microbiome, tissue engineering and biomaterials, cell therapy and regenerative medicine.

less

Noel B. Salazar

KU Leuven

Alejandra B Osorio

Wellesley College

Andrea Peto

Central European University

Armando Marques-Guedes

UNL - New University of Lisbon

Florin Curta

University of Florida

Stephen Whittle

Manchester Metropolitan University

Paola Bacchetta

University of California, Berkeley

Jaime VALENZUELA MÁRQUEZ

Pontificia Universidad Catolica de Chile

José Manuel Santos

University of Salamanca

Haris Tsavdaroglou

University of Amsterdam

Interests

Uploads

Papers by Najib Alidrissi

FTO gene Variants (rs9939609, rs8050136 and rs17817449) and type 2 diabetes mellitus risk: A Meta-Analysis

Gene

Self-care intervention using mobile apps for sexual and reproductive health in the WHO Eastern Mediterranean Region

Informatics for Health and Social Care

Management of Chemotherapy-Induced Nausea and Vomitting in Breast Cancer Patients: A Prospective Cohort Study

Journal of Oncology Research Reviews & Reports, Sep 30, 2022

Through a prospective cohort study we aimed to optimize prevention and management of chemotherapy... more Through a prospective cohort study we aimed to optimize prevention and management of chemotherapy-induced nausea and vomiting (CINV) in the emergence of new therapies for breast cancer patients. We included breast cancer patients treated with moderate emetogenic (MEC) or highly emetogenic chemotherapy (HEC) all stages combined, from April 2021 to November 2021. Patients were required to answer a survey of 32 questions in order to analyze the potential involvement of known and unknown risk factors in the occurrence of CINV. The acute phase of CINV was defined as nausea and vomiting that developed ≤ 24 hours after the start of chemotherapy. Delayed phase of CINV was defined as nausea and vomiting that developed > 24 hours after the start of chemotherapy. The severity of nausea and vomiting was evaluated with common terminology criteria for adverse events (CTCAE) v5.0; publish to date: November 27, 2017. Analysis and results were performed using JAMOVI statistical software. In total, 177 patients received chemotherapy, 103 patients(58%) received (HEC), and 74 patients (42%) received (MEC). All patients were female (100%). Risk factors associated to occurrence of CINV included previously known factors: Younger age than 50 years (29,8%), history of pregnancy-related nausea and vomiting (74,7%), alcohol use (no patient reported previous alcohol consumption), failure to adhere to antiemetic treatment guidelines (9,6%). The compliance with treatment score (90,4%) showed a good commitment of the patients in the process of their medical healthcare. Other potential risk factors have been also explored to determine their involvement or not in the occurrence of CINV (cancer stage, performance status, education level, chemotherapy protocols, the use of traditional herbs known as an antibacterial agent and immunity booster in our context). In the acute phase, (78%) of patients experienced nausea and (47,8%) experienced vomiting. In the delayed phase, (37,1%) of patients experienced nausea and only (15,3%) experienced vomiting. The severity of nausea and vomiting was evaluated according to CTCAE v5.0 in both groups HEC and MEC. Only (8,7%) had to stop treatment for non-tolerance (table 1-2). The present study demonstrated that high compliance to treatment guidelines for CINV and individualized care could lead to more optimal management of CINV.

Najib Alidrissi

Uploads

Papers by Najib Alidrissi

Log In